



Market Announcement

17 August 2022

Antisense Therapeutics Limited (ASX: ANP) – Suspension from Quotation

Description

The securities of Antisense Therapeutics Limited ('ANP') will be suspended from quotation immediately under Listing Rule 17.2, at the request of ANP, pending the release of an announcement relating to the request for a trading halt on 15 August 2022.

Issued by

Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)

For personal use only

17 August 2022

Ms Melissa Kostopoulos
Adviser, Listings Compliance
ASX Compliance Pty Ltd
Level 4, North Tower, Rialto Towers
525 Collins Street
Melbourne VIC 3000

BY EMAIL: tradinghaltsmelbourne@asx.com.au

Dear Melissa

Antisense Therapeutics Limited (ASX: ANP) – Request for voluntary suspension

Pursuant to ASX Listing Rule 17.2, Antisense Therapeutics Limited ACN 095 060 745 (the Company) requests voluntary suspension of its securities effective immediately while the Company works with the ASX in relation to the request for trading halt on 15 August 2022.

The Company requests that trading in its securities be suspended until the matter is resolved.

The Company is not aware of any reason why this request for voluntary suspension should not be granted.

Please contact me if you require any further information.

Yours sincerely

Phillip Hains
Joint Company Secretary